Article

Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study

Department of Epidemiology, Institute of Public Health, Aarhus University, Bartolin Allé 2, DK-8000 Aarhus, Denmark.
BMJ (online) (Impact Factor: 16.38). 09/2009; 339:b3569. DOI: 10.1136/bmj.b3569
Source: PubMed

ABSTRACT To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations.
Population based cohort study.
493 113 children born in Denmark, 1996-2003.
Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005.
Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low-for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI.
There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.

0 Bookmarks
 · 
129 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy.DesignCase–control study using data from national registers.SettingDenmark, Finland, and Norway during the period 1996–2007.PopulationA total of 14 902 women were included as cases and 148 929 women were included as controls.Methods Cases were women with elective termination of pregnancy at 12–23 weeks of gestation. Controls continued their pregnancy and were matched with cases on key factors.Main outcome measuresAssociation between antidepressant use during pregnancy and elective termination of pregnancy at 12–23 weeks of gestation for fetal anomalies, or for maternal ill health or socio-economic disadvantage.ResultsAt least one prescription of antidepressants was filled by 3.7% of the cases and 2.2% of the controls. Use of any type of antidepressant was associated with elective termination of pregnancy for maternal ill health or socio-economic disadvantage (odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0–2.5). Elective termination of pregnancy for fetal anomalies was associated with the use of mirtazapine (OR 2.2, 95% CI 1.1–4.5). There was no association between the use of any of the other antidepressants and elective termination of pregnancy for fetal anomalies.Conclusions The use of any type of antidepressants was associated with elective termination of pregnancy at 12–23 weeks for maternal ill health or socio-economic disadvantage, but not with terminations for fetal anomalies. Further studies need to confirm the findings concerning mirtazapine and termination of pregnancy for fetal anomalies.
    BJOG An International Journal of Obstetrics & Gynaecology 11/2014; DOI:10.1111/1471-0528.13164 · 3.76 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract in French and in English Résumé La grossesse et le postpartum sont des périodes particulières concernant l’utilisation de psychotropes chez la future mère. La prescription thérapeutique doit tenir compte du risque éventuel de malformation chez le fœtus, de syndrome de sevrage chez le nouveau-né, du type d’allaitement et du risque potentiel de la maladie mentale maternelle non traitée. Les recommandations de bonne pratique sont en perpétuel remaniement et leurs conclusions parfois contradictoires. Méthode : le but de ce travail est d’élaborer un référentiel actualisé à partir d’une revue de la littérature, facile d’utilisation pour tout professionnel concerné par le suivi ou la prescription d’un traitement psychotrope (antidépresseurs, anxiolytiques-hypnotiques, neuroleptiques, thymorégulateurs et traitements de substitution de la dépendance aux opiacés) chez une femme enceinte ou qui allaite. Résultats : ces mises au point, sous forme de tableaux, se basent également sur notre expérience clinique en tant qu’équipe spécialisée en médecine périnatale. Summary Pregnancy and the postpartum periods are particular for the mother's use of drugs. Therapeutic prescription must take into account the potential risk of fetal malformation, newborn's withdrawal syndrome, feeding type and potential risk of untreated maternal mental illness. Recommendations for good practice are constantly remodeling and their conclusions are sometimes contradictory. Method: The aim of this work is to develop an updated review, easy to use for any professional involved in the monitoring or prescription of a psychotropic medication (antidepressants, anxiolytics-hypnotics, neuroleptics, mood stabilizers and substitution treatment of opioid dependance) for pregnant or nursing women. Results: These updates in tabular form are also based on our clinical experience as a team specializing in perinatal medicine.
    La Presse Médicale 01/2015; 44(3):271-283. DOI:10.1016/j.lpm.2014.07.026 · 1.17 Impact Factor

Full-text (2 Sources)

Download
45 Downloads
Available from
May 29, 2014